One-week once-daily triple therapy with esomeprazole, Moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

Helicobacter

Volumn 13, Issue 1, 2008, Pages 69-74

  Miehlke, Stephan ^a   Schneider Brachert, Wulf ^b   Kirsch, Christian ^a   Morgner, Andrea ^a   Madisch, Ahmed ^a   Kuhlisch, Eberhard ^a   Haferland, Christian ^c   Bästlein, Elke ^c   Jebens, Claus ^c   Zekorn, Christian ^c   Knoth, Holger ^a   Stolte, Manfred ^d   Lehn, Norbert ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c Gastroenterologists in Private Practice   (Germany)

^d INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

Clarithromycin; CYP2C19 polymorphism; Esomeprazole; Fluoroquinolones; Helicobacter pylori; Levofloxacin; Metronidazole; Moxifloxacin; Resistance; Rifabutin

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PROTON PUMP INHIBITOR; RIFABUTIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; FEVER; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; AZA COMPOUNDS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; QUINOLINES; RIFABUTIN;

HELICOBACTER PYLORI;

EID: 38149058786     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00588.x     Document Type: Article

References (30)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007 [Epub ahead of print].
2. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M. Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med 1999 159 : 1562 6.
3. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002 16 : 1269 75.
4. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000 19 : 538 41.
5. Wang WH, Wong BC, Mukhopadhyay AK, Berg DE, Cho CH, Lai KC, Hu WH, Fung FM, Hui WM, Lam SK. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000 14 : 901 10.
6. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006 23 : 35 44.
7. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006 101 : 488 96.
8. Morgner A, Labenz J, Miehlke S. Effective regimes for the treatment of Helicobacter pylori Infection. Expert Opin Invest Drugs 2006 15 : 995 1016.
9. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 84.
10. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000 14 : 45 50.
11. Blondeau JM, Hansen GT. Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opin Pharmacother 2001 2 : 317 35.
12. Di Caro S, Ojetti V, Zocco MA, Cremonini F, Bartolozzi F, Candelli M, Lupascu A, Nista EC, Cammarota G, Gasbarrini A. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002 16 : 527 32.
13. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005 21 : 1241 7.
14. Cheon JH, Kim N, Lee DH, Kim JW, Hwang JH, Park YS, Kim JM, Suh SO, Jung HC, Song IS. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection. Korean J Gastroenterol 2005 45 : 111 7.
15. Cheon JH, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006 11 : 46 51.
16. Kirsch C, Morgner A, Miehlke S. Relevance of cytochrome P450 polymorphism in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Current Pharmacogenomics 2006 4 : 47 56.
17. Malfertheiner P, Megraud F, O'Morain CO, O'Morain CO, Hungins APS, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 80.
18. Dixon MF, Genta RM, Yardley JH, Correa P. and the participants in the International Workshop on the Histopathology of Gastritis, Houston 1994. Classification and grading of gastritis: the updated Sydney System. Am J Surg Pathol 1996 20 : 1161 81.
19. Wong WM, Gu Q, Lam SK, et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 : 553 60.
20. Miehlke S, Hansky K, Schneider-Brachert W, et al. Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Aliment Pharmacol Ther 2006 24 : 395 403.
21. Gisbert JP, Gisbert JL, Marcos S, Olivares D, Pajares JM. Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther 2005 22 : 1041 6.
22. Lamouliatte H, Megraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, Fauchere JL, Labigne A, Flejou JF, Barthelemy P. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003 18 : 791 7.
23. Miwa H, Nagahara A, Kurosawa A, Ohkusa T, Ohkura R, Hojo M, Enomoto N, Sato N. Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 2003 17 : 1545 51.
24. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bästlein E, Vieth M, Stolte M, Lehn N, Bayerdörffer E. A prospective, randomized study of quadruple therapy and high-dose omeprazole/amoxicillin therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003 8 : 310 9.
25. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007 29 : 389 96.
26. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 5.
27. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007 51 : 346 9.
28. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006 101 : 1467 75.
29. Schwab M, Schaeffeler E, Klotz U, Treiber G. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004 76 : 201 9.
30. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaaaeko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001 69 : 158 68.